Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Pilot Study of Biomarker Evaluation and Safety of Pre-Incisional Ketorolac for Patients Undergoing Surgical Resection for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04495894
• Other study ID #: STUDY00000205
• Status: Recruiting
• Phase: Early Phase 1
• Start date: August 24, 2020
• Est. completion date: October 2024

Study information

• Verified date: October 2023
• Source: Emory University
• Contact: Viraj Master, MD, PhD
• Phone: 404-778-4898
• Email: vmaster[@]emory.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for patients undergoing surgical resection for non-small cell lung cancer and renal cell carcinoma. There is significant promise in the use of preoperative ketorolac to decrease the inflammatory response after surgical resection of tumors, thereby potentially reducing the risk of distant metastatic tumor spread and improving survival. A total of 56 patients (28 per disease site) will be enrolled into the experimental arm and will receive ketorolac prior to surgery. About 10 patients will be allocated randomly into a control group, for each disease site, for a total of 76 patients enrolled. The research will advance scientific knowledge by studying the safety of a preoperative dose of ketorolac prior to major surgical resection, which needs to be assessed prior to proceeding with a larger phase II study designed to evaluate traditional efficacy endpoints such as recurrence and overall survival.

Description:

Surgical resection is a cornerstone of standard-of-care treatment for early-stage non-small cell lung carcinoma (NSCLC) and renal cell carcinoma (RCC). Yet despite optimal treatment, many of these patients will develop cancer recurrence within the first few years. For example, the 5-year survival rate for patients with stage I/II NSCLC is only around 55%. As a result, more effective treatments that decrease cancer recurrence and increase survival are still needed. Surgery induces inflammation, immunosuppression and angiogenesis. Although these processes are important for wound healing in response to tissue injury caused by surgery, they also support the survival, growth and dissemination of any remaining cancer cells and can lead to systemic recurrence soon after surgery. Surgical trauma increases the production of prostaglandins and thromboxanes, which have tumor-promoting and immunosuppressive activities, and reduces the activity of natural killer cells, which impairs the ability of the immune system to keep cancer cells in check. However, if given just before tissue injury, non-steroidal anti-inflammatory drugs (NSAIDs) may be able to block the production of prostaglandins/thromboxanes and boost the activity of natural killer cells, and thereby decrease the risk of cancer recurrence. NSAIDs such as ketorolac are already routinely given to cancer patients postoperatively for pain management and are sometimes given intraoperatively (immediately before or during surgery) to prevent postoperative pain. A retrospective clinical analysis found that intraoperative intravenous ketorolac or diclofenac (another NSAID), when added to standard of care for patients with stage I/II NSCLC, was associated with decreased risks of distant recurrence and mortality. There is significant promise in the use of preoperative ketorolac to decrease the inflammatory response after surgical resection of tumors, thereby potentially reducing the risk of distant metastatic tumor spread and improving survival. Patients will be screened and recruited during the preoperative period by the responsible medical and surgical team. Blood will be drawn preoperatively and then at the end of the surgical procedure. Participants will be randomized to either preoperative ketorolac group or a concurrent control group who will not receive preincisional ketorolac. The concurrent control group is to obtain untreated biologic samples for biologic correlative studies and secondary endpoints. These patients will not be compared to the investigational cohort in regards to the primary endpoint of safety. Patients will be randomized on the day of surgery to either the experimental or control arms and participants will be followed or 28 days. Medical records will be reviewed at 1 and 2 years post-surgery for survival assessment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Pathology-proven or suspected stage 1 or 2 NSCLC and Stage 3 tumor stage 3, node stage 0 (T3N0) RCC, that require surgical resection as the treatment of choice
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Ability to understand and the willingness to sign an informed written consent

Exclusion Criteria:

• Individuals with pure lung ground-glass opacity (GGO) lesions or mixed GGO with <50% solid component
• Patients undergoing pneumonectomy
• History of cancer in the 3 years prior to surgery (except for basal-cell carcinoma of the skin or cervical neoplasia).
• Contraindication for NSAIDs, including peptic ulcer disease, preoperative chronic kidney disease with estimated glomerular filtration rate (eGFR) <45, allergies or intolerance to NSAIDs, coagulation disorder, or age > 80 years
• Having taken an NSAID within 5 days prior to surgery
• Immunocompromised status
• Refusal or inability to understand the protocol and consent form or to receive follow-up in line with the recommendations
• Preoperative hemoglobin < 9.0

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Renal Cell
• Lung Neoplasms
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Intervention

Drug:
• Preoperative Ketorolac
30 mg ketorolac will be administered intravenously 30 minutes prior to incision.

Locations

Country	Name	City	State
United States	Emory Clinic	Atlanta	Georgia
United States	Emory University Hospital	Atlanta	Georgia
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	Winship Cancer Institute	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Transcriptome Analysis	Transcriptome analysis will be performed to evaluate the effects of ketorolac on immune response pathways.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Other	Change in Flow Cytometry	Flow Cytometry will be performed to evaluate the effects of ketorolac on immune response pathways.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Other	Change in T-Cell Receptor (TCR) Sequencing	T-Cell receptor (TCR) sequencing will be performed to evaluate the effects of ketorolac on immune response pathways.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Other	Change in Single Cell RNA Sequencing	Single cell RNA sequencing will be performed to evaluate the effects of ketorolac on immune response pathways.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Primary	Incidence of Blood Transfusion Among Ketorolac Group	Hemorrhagic side effects among participants receiving ketorolac preoperatively will be assessed as the need for blood transfusions before being discharged from the hospital after surgery. The need for a blood transfusion is defined as greater than two units of blood, which are not related to vascular injury due to technical considerations or complications, as determined by the operating surgeon.	Prior to Hospital Discharge (generally up to 7 days post surgery)
Primary	Incidence of Clinically Significant Hematoma Development Among Ketorolac Group	Significant hematoma development will be assessed among participants receiving ketorolac.	Prior to Hospital Discharge (generally up to 7 days post surgery)
Primary	Incidence of Return to the Operating Room for Bleeding Among Ketorolac Group	The need for returning to the operating room for bleeding, as determined by the treating surgeon, will be assessed among participants receiving ketorolac.	Prior to Hospital Discharge (generally up to 7 days post surgery)
Primary	Incidence of Postoperative Renal Failure Among Ketorolac Group	Postoperative renal failure among participants receiving ketorolac will be assessed.	Prior to Hospital Discharge (generally up to 7 days post surgery)
Primary	Incidence of Postoperative Morbidity Rate Among Ketorolac Group	Postoperative morbidity among participants receiving ketorolac will be assessed.	Prior to Hospital Discharge (generally up to 7 days post surgery)
Secondary	Change in Interleukin-1 alpha (IL-1alpha) Levels	IL-1alpha levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interleukin-1beta (IL-1ß) Levels	IL-1beta levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interleukin-2 (IL-2) Levels	IL-2 levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interleukin-6 (IL-6) Levels	IL-6 levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interleukin-8 (IL-8) Levels	IL-8 levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interleukin-10 (IL-10) Levels	IL-10 levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interleukin-12p70 (IL-12p70) Levels	IL-12p70 levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Tumor Necrosis Factor-alpha (TNF-alpha) Levels	TNF-alpha levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Interferon (INF)-gamma Levels	INF-gamma levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Levels	GM-CSF levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Secondary	Change in Monocyte Chemotactic and Activating Factor (MCAF) Levels	MCAF levels will be compared between study arms.	Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28